Open AccessAngiogenesis’ related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients
Author(s) -
Angelo Borsarelli Carvalho Brito,
Márcia Torresan Delamain,
Marcello Ferretti Fanelli,
Fernando Augusto Soares,
Carmino Antônio De Souza,
José Vassallo,
Carmen Sílvia Passos Lima
Publication year - 2021
Publication title -
tumor biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1423-0380
pISSN - 1010-4283
DOI - 10.3233/tub-211510
Subject(s) - vascular endothelial growth factor a , lymphoma , genotype , diffuse large b cell lymphoma , angiogenesis , haplotype , chop , cancer research , medicine , oncology , vascular endothelial growth factor , biology , vegf receptors , gene , genetics
OBJECTIVES: Single nucleotide variants (SNVs) in vascular endothelial growth factor A (VEGFA) and VEGFA receptor (KDR) genes confer different inherited abilities in angiogenesis (AG) pathway. We aimed in the present study to evaluate influence of six VEGFA and four KDR SNVs in clinical features and survival of diffuse large B-cell lymphoma (DLBCL) patients. METHODS: One hundred and sixty-eight DLBCL patients diagnosed between June 2009-September 2014 were enrolled in the study. Patients were homogeneously treated with R-CHOP. Genotypes were identified in genomic DNA by real-time polymerase chain reaction. RESULTS: Patients with VEGFA -634CC and +936CT or TT genotypes were at increased risk of showing grade III / IV toxicities and not achieving complete remission with treatment, and shorter event-free and overall survival were seen in patients with VEGFA -1154GA or AA genotype and VEGFA ATAGCC haplotype. CONCLUSION: Our data suggest that inherited abnormalities in AG’s gene modulate clinical features and prognosis of DLBCL patients homogeneously treated with R-CHOP.